AT515178A5 - Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie - Google Patents

Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie Download PDF

Info

Publication number
AT515178A5
AT515178A5 ATA9306/2013A AT93062013A AT515178A5 AT 515178 A5 AT515178 A5 AT 515178A5 AT 93062013 A AT93062013 A AT 93062013A AT 515178 A5 AT515178 A5 AT 515178A5
Authority
AT
Austria
Prior art keywords
curcumin
minimize
nanocurcumin
plga
liposomal
Prior art date
Application number
ATA9306/2013A
Other languages
English (en)
Other versions
AT515178A2 (de
Inventor
Amalendu Prakash Ranjan
Anindita Mukerjee
Jamboor K Vishwanatha
Lawrence Helson
Original Assignee
Univ North Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Texas filed Critical Univ North Texas
Publication of AT515178A2 publication Critical patent/AT515178A2/de
Publication of AT515178A5 publication Critical patent/AT515178A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die vorliegende Erfindung beinhaltet Zusammensetzungen und Verfahren zum Herstellen einer Nanopartikel-Zusammensetzung, welche einen polymeren Kern enthält, der mindestens ein Polymer und mindestens einen Wirkstoff und mindestens eine Schicht mindestens eines Lipids auf der Oberfläche des polymeren Kerns enthält; insbesondere betrifft die Erfindung die Verwendung von Curcumin in einer solchen Lipid-Polymer-Nanopartikel-Formulierung zur Minimierung der QT-Verlängerung in Verbindung mit Curcumin bei der Behandlung von Krebs.
ATA9306/2013A 2012-08-31 2013-08-31 Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie AT515178A5 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695827P 2012-08-31 2012-08-31
US14/016,056 US9138411B2 (en) 2012-08-31 2013-08-31 Curcumin-ER, a liposomal-PLGA sustained release nanocurcumin for minimizing QT prolongation for cancer therapy

Publications (2)

Publication Number Publication Date
AT515178A2 AT515178A2 (de) 2015-06-15
AT515178A5 true AT515178A5 (de) 2015-07-15

Family

ID=50184475

Family Applications (1)

Application Number Title Priority Date Filing Date
ATA9306/2013A AT515178A5 (de) 2012-08-31 2013-08-31 Curcumin-er, ein nanocurcumin aus liposomalem plga mit anhaltender freisetzung zur minimierung der qt-verlängerung zur krebstherapie

Country Status (5)

Country Link
US (2) US9138411B2 (de)
AT (1) AT515178A5 (de)
CA (1) CA2882978A1 (de)
DE (1) DE112013004278T5 (de)
WO (1) WO2014036534A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US12004868B2 (en) 2011-06-03 2024-06-11 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
WO2012167212A2 (en) 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
WO2015095576A1 (en) 2013-12-18 2015-06-25 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
EP3207931A3 (de) 2014-06-03 2017-12-20 Signpath Pharma Inc. Schutzwirkung von dmpc, dmpg, dmpc/dmpg, egpg, lysopg und lysopc gegen arzneimittel, die kanalopathien hervorrufen
RU2571270C1 (ru) * 2014-07-17 2015-12-20 Открытое Акционерное Общество "Фаберлик" Липосомальное наносредство на основе продуктов, полученных из корневищ куркумы
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
WO2016167732A1 (en) 2015-04-17 2016-10-20 Sezgi̇n Veliddin Canfeza Development of curcumin and piperine loaded double-layered biopolymer based nano delivery systems by using electrospray / coating method
KR102638618B1 (ko) 2016-04-27 2024-02-21 사인패스 파마 인코포레이티드 약물 유발된 방실 차단의 방지
MX2019004222A (es) * 2016-10-19 2019-06-10 Signpath Pharma Inc Efecto protector de dmpc, dmpg, dmpc/dmpg, lysopg y lysopc contra farmacos que provocan canalopatias.
CA3076820A1 (en) 2017-10-19 2019-04-25 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies
US10912843B2 (en) * 2018-04-04 2021-02-09 National Cheng Kung University Endoplasmic reticulum-targeting nanovehicles and methods for use thereof
TWI737974B (zh) * 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
US20210315830A1 (en) 2018-08-31 2021-10-14 Council Of Scientific And Industrial Research A curcumin loaded stabilized polymeric nanoparticles with increased solubility and photo-stability and a green process for the synthesis thereof
CN109381447B (zh) * 2018-12-10 2021-01-26 上海交通大学医学院附属第九人民医院 一种载虾青素磷脂纳米粒及其制备方法与应用
KR102353979B1 (ko) * 2020-02-28 2022-01-20 가천대학교 산학협력단 전기분무로 제조된 고분자 리포좀 나노입자 제조방법
WO2021176264A1 (en) * 2020-03-02 2021-09-10 Yogesh Dound Liposomal compositions and process for preparation thereof
CN116963724A (zh) * 2021-03-03 2023-10-27 萨恩帕斯药物有限公司 用于人类恶性胸腔积液的治疗
CN116173233A (zh) * 2023-01-30 2023-05-30 北京大学第一医院 Pd-1靶向负载姜黄素的纳米制剂、制备及在肾脏疾病的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048598A1 (en) * 1997-06-13 2002-04-25 Navid Malik Internally supported lipid vesicle systems
WO2007103435A2 (en) * 2006-03-06 2007-09-13 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US20080138400A1 (en) * 2004-03-05 2008-06-12 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20080253961A1 (en) * 2007-04-13 2008-10-16 University Of North Texas Health Science Center At Fort Worth Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics
US20110117186A1 (en) * 2009-11-19 2011-05-19 Lawrence Helson Intravenous infusion of curcumin and a calcium channel blocker

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US4812312A (en) 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
US5679864A (en) 1995-11-03 1997-10-21 Gene Print Inc. Process for the synthesis of curcumin-related compounds
JP3272256B2 (ja) 1997-01-17 2002-04-08 丸善製薬株式会社 クルクミノイドの安定化法および安定化クルクミノイド組成物
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US20010051184A1 (en) 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
JP5106738B2 (ja) 2000-09-06 2012-12-26 ジョンズ・ホプキンス・ユニバーシティ 心不整脈治療法
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
EG23547A (en) 2002-11-25 2006-05-10 Mallah Ahmed Ibrahim Mohame El Preparation of a topical pharmaceutical preparation of curcumin alone or a combination of circumin plus capsaicin as an effective remedy for treatmentof peripheral neuropathies
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
WO2004080396A2 (en) 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Liposomal curcumin for treatment of cancer
US7674820B2 (en) 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
EP1658061A2 (de) 2003-08-26 2006-05-24 Research Development Foundation Aerosolabgabe von curcumin
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
AU2005219413A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
US20080103213A1 (en) 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
US20050233970A1 (en) 2004-03-23 2005-10-20 Praecis Pharmaceuticals, Inc. Methods for treating long QT syndrome
NZ552451A (en) 2004-07-09 2010-07-30 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
JP4990786B2 (ja) 2004-11-05 2012-08-01 イネックス ファーマシューティカルズ コーポレイション 薬物リポソーム製剤を安定化するための組成物および方法
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
ITMI20042353A1 (it) 2004-12-10 2005-03-10 Uni Degli Studi Di Modena E Re Peptidi per la veicolazione di farmaci
US8202839B1 (en) 2005-01-04 2012-06-19 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
JP5039032B2 (ja) 2005-05-30 2012-10-03 アントニイ ベニー クルクミンの生物学的利用率を向上させるための組成物
JP2009500664A (ja) 2005-06-30 2009-01-08 ソリユテイア・インコーポレイテツド 耐衝撃性直接接触プラズマディスプレイパネルフィルタ
US20100048957A1 (en) 2006-06-05 2010-02-25 Kim Darrick S H L Method to prepare pure curcumin
US7507864B2 (en) 2006-08-01 2009-03-24 Salisbury University Method for the synthesis of curcumin analogues
US20080075671A1 (en) 2006-09-22 2008-03-27 Di Mauro Thomas M Intranasally administering curcumin to the brain to treat alzheimer's disease
US7593764B2 (en) 2006-10-03 2009-09-22 General Electric Company System and method of serial comparison for detection of long QT syndrome (LQTS)
CA2665343C (en) 2006-10-05 2014-12-16 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
JP2010506836A (ja) 2006-10-12 2010-03-04 リサーチ ファウンデイション オブ ザ シティー ユニヴァーシティ オブ ニューヨーク 新規なクルクミンおよびテトラヒドロクルクミン誘導体
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
WO2008063513A2 (en) 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
US7871609B2 (en) 2007-03-02 2011-01-18 Sam Ziff Supplements for pain management
US20080255464A1 (en) 2007-04-10 2008-10-16 Vincent G Michael System and method for diagnosing and treating long qt syndrome
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
US20090246770A1 (en) 2007-11-01 2009-10-01 Andrew Levy Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2
US8062663B2 (en) 2008-05-23 2011-11-22 National Health Research Instittues Methods and compostions for enhancing transdermal drug delivery
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010009186A1 (en) 2008-07-15 2010-01-21 The Board Of Trustees Of The University Of Illinois Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein
US20100179103A1 (en) 2008-07-21 2010-07-15 Ketan Desai Curcumin cyclodextrin combination for preventing or treating various diseases
US20120003177A1 (en) 2008-09-17 2012-01-05 Youqing Shen Curcumin-containing polymers and water-soluble curcumin derivatives as prodrugs of prodrug carriers
US20100093873A1 (en) 2008-10-02 2010-04-15 Goldfischer Sidney L Methods of improving therapy of perfluorocarbons (PFC)
WO2010057332A1 (en) 2008-11-19 2010-05-27 Telefonaktiebolaget L M Ericsson (Publ) Provisioning method and system
US20120021036A1 (en) 2009-01-15 2012-01-26 The Regents Of The University Of California Composite nanostructures and methods for making and using them
US7723515B1 (en) 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
CN102421424A (zh) 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
CN102470098A (zh) 2009-07-01 2012-05-23 皇家飞利浦电子股份有限公司 用于mpi引导的药物递送的刺激-响应性载体
US9393198B2 (en) 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
US20120058208A1 (en) 2010-09-04 2012-03-08 Synthite Industries Ltd. Synergistic Composition for Enhancing Bioavailability of Curcumin
US9447027B2 (en) 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
EP2685963A4 (de) 2011-03-16 2014-11-19 Signpath Pharma Inc Curcumin-kombination mit wirkstoffen gegen diabetes vom typ 2 und zur behandlung von krankheits-folgeleiden, wirkstoffvermittelten nebenwirkungen und verbesserter glykämiesteuerung
WO2012167212A2 (en) 2011-06-03 2012-12-06 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
JP2015522810A (ja) 2012-06-14 2015-08-06 サインパス ファルマ, インク.Signpath Pharma, Inc. リポソームのクルクミン及びその代謝産物であるテトラヒドロクルクミンの薬物動態を測定するための方法及びシステム

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048598A1 (en) * 1997-06-13 2002-04-25 Navid Malik Internally supported lipid vesicle systems
US20080138400A1 (en) * 2004-03-05 2008-06-12 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
WO2007103435A2 (en) * 2006-03-06 2007-09-13 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders
US20080253961A1 (en) * 2007-04-13 2008-10-16 University Of North Texas Health Science Center At Fort Worth Formulation of Active Agent Loaded Activated PLGA Nanoparticles for Targeted Cancer Nano-Therapeutics
US20110117186A1 (en) * 2009-11-19 2011-05-19 Lawrence Helson Intravenous infusion of curcumin and a calcium channel blocker

Also Published As

Publication number Publication date
US9138411B2 (en) 2015-09-22
CA2882978A1 (en) 2014-03-06
DE112013004278T5 (de) 2015-05-21
US20140065061A1 (en) 2014-03-06
AT515178A2 (de) 2015-06-15
WO2014036534A1 (en) 2014-03-06
US20150258026A1 (en) 2015-09-17

Similar Documents

Publication Publication Date Title
JP2016504362A5 (de)
AR128748A2 (es) Compuestos sustituidos de aminopurina, sus composiciones y métodos de tratamiento con ellos
NZ630912A (en) Nanoparticle compositions of albumin and paclitaxel
EP3524268A4 (de) Verwendung einer kombination aus einem anti-pd-1-antikörper und vegfr-inhibitor bei der herstellung eines arzneimittels zur behandlung von krebs
BR112017016093A2 (pt) composição sólida, curativo de ferida, e, método de fabricação de uma composição
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
EP3424907A3 (de) Verbindungen und organische elektronische vorrichtungen
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
BR112017016100A2 (pt) composição, curativo de ferida, e, método de fabricação de uma composição.
BR112017007301A2 (pt) estruturas fibrosas solúveis e métodos para a fabricação das mesmas
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112017016072A2 (pt) ?composição, curativo de ferida, e, método de fabricação de uma composição?
UY36665A (es) Derivados de ciclohexano sustituidos con amidas
AR091220A1 (es) Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
WO2015152693A3 (ko) 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
WO2015013635A3 (en) Inhibitors of transcription factors and uses thereof
WO2017017063A3 (en) Nanoparticle-based liver-targeting therapy and imaging
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
AR102926A1 (es) Composiciones anticancerosas
CO2018007278A2 (es) Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan
WO2016193810A8 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
CO6470803A2 (es) Una formulacion novedosa de meloxicam
GB2515956A (en) Anti-Adherent Formulation Including an Anionic or nonionic polymer
MX2017001863A (es) Nanoparticulas cargadas con glucocorticoides para prevencion de rechazo de aloinjerto corneal y neovascularizacion.
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr

Legal Events

Date Code Title Description
REJ Rejection

Effective date: 20180215